A review of studies found that the time from symptom onset to confirmation of diagnosis of multiple myeloma can be significantly reduced. Currently, many patients experience a more than 3-month delay until their diagnosis is confirmed.
A review of studies found that the time from symptom onset to confirmation of diagnosis of multiple myeloma can be significantly reduced. Currently, many patients experience a more than 3-month delay until their diagnosis is confirmed.
A paper published in BMJ Open reviewed 9 studies that reported time intervals from symptom onset to diagnosis. Delays in diagnosis can cause complications to develop, such as pathological fractures and irreversible renal failure, they are linked to higher cancer stage and poorer survival, as well as a shorter disease-free survival and more complications following treatment.
“Quantifying the time intervals leading up to diagnosis is important as it will inform future interventions that aim to shorten the diagnostic process,” the authors explained.
Five of the studies reported intervals in various cancers, 3 reported only for multiple myeloma, and 1 for hematological malignancies. There was substantial diversity among the studies in the symptoms and the time points used to define intervals. Three of the studies didn’t even report the starting symptoms, and in total there were 19 different symptoms used to define the start of multiple myeloma.
The researchers found that patients experienced symptoms of the beginning of multiple myeloma for a median of 1 month before seeking help and 25% patients waited for longer than 3 months. After seeking care, the median time to diagnosis was 108.6 days, with 25% of patients waiting longer than 8 months.
The reasons for such long diagnostic intervals include the fact that symptoms like back pain are common; general practitioners have a hard time suspecting multiple myeloma when patients visit with symptoms since it is a rare disease; and there is no effective screening program.
Since this paper was not able to estimate the interval from referral to diagnosis care directly, the authors suggested that future studies estimate this duration and investigate the impact of 1 setting on the other.
“There is potential for meaningful reductions in the time to diagnosis especially for the diagnostic interval, which could improve patient outcomes, but more research is required in order to do that,” the authors concluded.
Reference
Koshiaris C, Oke J, Abel L, Nicholson BD, Ramasamy K, Van den Bruel A. Quantifying intervals to diagnosis in myeloma: a systematic review and meta-analysis. BMJ Open. 2018;8:e019758. doi: 10.1136/bmjopen-2017-019758.
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Community Engagement, Culturally Tailored Care as a Gateway to Advancing Health Equity
October 16th 2024Many talks at the Association of Cancer Care Centers (ACCC) 41st National Oncology Conference advocated for the adoption of culturally relevant care, the leveraging of community partnerships, and community engagement to build better trust with patients and improve outcomes.
Read More